Zobrazeno 1 - 10
of 250
pro vyhledávání: '"Michael, Hubalek"'
Autor:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Clemens Schmitt, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Christian Fridolin Singer, Florian Roitner, Christopher Hager, Johannes Andel, Michael Hubalek, Michael Knauer, Richard Greil
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-9 (2021)
Abstract Background About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a
Externí odkaz:
https://doaj.org/article/455c23fb65a7493d9d187d0827208969
Autor:
Guenther G. Steger, Daniel Egle, Rupert Bartsch, Georg Pfeiler, Edgar Petru, Richard Greil, Ruth Helfgott, Christian Marth, Leopold Öhler, Michael Hubalek, Alois Lang, Christoph Tinchon, Ferdinand Haslbauer, Andreas Redl, Karin Hock, Mathias Hennebelle, Bernhard Mraz, Michael Gnant
Publikováno v:
Breast, Vol 50, Iss , Pp 64-70 (2020)
Background: STEPAUT, an Austrian non-interventional study, evaluated the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast c
Externí odkaz:
https://doaj.org/article/7f2b64fd23e24290aaa6209341e7250f
Autor:
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, Michael Hubalek, Edgar Petru, Margit Sandholzer, Johannes Andel, Marija Balic, Thomas Melchardt, Cornelia Hauser-Kronberger, Clemens A. Schmitt, Hanno Ulmer, Richard Greil
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase II trial of bendamustine in combinati
Externí odkaz:
https://doaj.org/article/081f6e257034454ea219ac5bd0a1bfe1
Autor:
Gabriel Rinnerthaler, Simon P. Gampenrieder, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil
Publikováno v:
Cancer Research. 83:P3-05
Background: Hormone-receptor (HR) status, HER2 Status, de novo metastatic disease, distant recurrence-free interval (DRFI), and visceral disease are known prognostic factors in metastatic breast cancer (MBC). Therefore, in the majority of clinical tr
Autor:
Beate Jahn, Ursula Rochau, Christina Kurzthaler, Michael Hubalek, Rebecca Miksad, Gaby Sroczynski, Mike Paulden, Marvin Bundo, David Stenehjem, Diana Brixner, Murray Krahn, Uwe Siebert
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer (BC) to avoid unnecessary
Externí odkaz:
https://doaj.org/article/79ee22c649a441c7b25a724ef7caa827
Autor:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marij Balic, Sonja Heibl, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christopher Hager, Michael Knauer, Michael Hubalek, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-21
Background: BM are generally associated with poor prognosis and with neurological impairments making BM a major limitation of life expectancy and quality of life in MBC. Real-world data are needed in order to quantify and better characterize this spe
Autor:
Gabriel Rinnerthaler, Simon P Gampenrieder, Christoph Tinchon, Andreas Petzer Petzer, Marija Balic, Heibl Sonja, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christophe Hager, Michael Hubalek, Michael Knauer, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-16
Background: Despite the advances by targeted therapies, particularly in HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC), chemotherapy remains a mainstay of the treatment in all breast cancer subtypes. Response probabil
Autor:
Anne Oberguggenberger, Caroline Martini, Nathalie Huber, Lesley Fallowfield, Michael Hubalek, Martin Daniaux, Barbara Sperner-Unterweger, Bernhard Holzner, Monika Sztankay, Eva Gamper, Verena Meraner
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-9 (2017)
Abstract Background Cancer survivorship is of increasing importance in post-treatment care. Sexual health (SH) and femininity can be crucial issues for women surviving cancer. We aimed to determine a more complete understanding of the contribution th
Externí odkaz:
https://doaj.org/article/0988773794ac491b87935d13939d6698
Autor:
Caroline Linhart, Heribert Talasz, Evi M. Morandi, Christopher Exley, Herbert H. Lindner, Susanne Taucher, Daniel Egle, Michael Hubalek, Nicole Concin, Hanno Ulmer
Publikováno v:
EBioMedicine, Vol 21, Iss C, Pp 79-85 (2017)
Background: Previous studies on breast cancer (BC), underarm cosmetic products (UCP) and aluminum salts have shown conflicting results. We conducted a 1:1 age-matched case-control study to investigate the risk for BC in relation to self-reported UCP
Externí odkaz:
https://doaj.org/article/9580e9175fca40cf80c20c22b88af8c6
Autor:
Michael Gnant, J. Wayne Cowens, Shuzhen Liu, Sean Ferree, Carl Schaper, Christian Fesl, Harald Trapl, Michael Knauer, Michael Hubalek, Thomas Bauernhofer, Peter Dubsky, Brigitte Mlineritsch, Christian F. Singer, Elisabeth Müller-Holzner, Christine Gruber-Rossipal, Peter Regitnig, Otto Dietze, Zsuzsanna Bago-Horvath, Raimund Jakesz, Herbert Stöger, Richard Greil, Margaretha Rudas, Torsten O. Nielsen, Martin Filipits
PDF file - 34K, Supplementary Table S1. ROR cutoff values for risk groups defined by nodal status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20887cf3aa596363e0682b249ea375d2
https://doi.org/10.1158/1078-0432.22449326
https://doi.org/10.1158/1078-0432.22449326